Tor D Tosteson's research while affiliated with Dartmouth College and other places

... Dalam hasil penelitian ini, dinyatakan juga bahwa LVI merupakan faktor yang mempengaruhi prognosis dan outcome pasien. 42 Menurut penelitian yang dilakukan oleh Kuhn (2023), terdapat bukti kuat yang menunjukkan bahwa LVI pada karsinoma payudara berkaitan dengan karakteristik klinikopatologis yang lebih agresif, seperti ukuran tumor yang lebih besar, tingkat histologis yang lebih tinggi, staging T yang lebih tinggi, dan metastasis kelenjar getah bening aksila. LVI merupakan faktor prognostic negatif independent yang terkait dengan kekambuhan local dan distant metastasis serta DFS dan OS yang lebih buruk, bahkan pada pasien dengan kelenjar getah bening aktif. ...

... The formation of BM depends on the extravasation of tumor cells, perivascular tumor cell growth, and the co-option of pre-existing vessels in a complex multistep process [33][34][35]. In addition, cerebral perfusion and oxygenation are crucial for the effect of local radiotherapy on BM [36,37], and alterations in cerebral perfusion could also modulate the efficacy of systemic treatment [38,39]. Taking into account this relevant interplay of BM formation and treatment with vascular architecture, there is a strong need to more precisely understand the effects of vascular risk factors that could influence development and prognosis of BM. ...

... However, to date, none of these CBSIs have gained FDA approval, mainly due to their toxicity and lack of clinical benefits, problems that are related to their specific chemical structures. Compounds such as CA-4P, VERU-111, OXi4503, ABT-751, BNC105P and ZD6126 are currently undergoing or have completed clinical trials [17][18][19][20], but none are currently approved for clinical applications in cancer treatment due to their causation of undesirable adverse events [21], lack of bioavailability and low aqueous solubility [22,23]. Some other compounds are in preclinical studies. ...

... Saudi Arabia (46), China (21), and Canada (38) each contributed to publish one relevant study. Most of the article (n = 17) were published in 2022 [32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48]. Table 2 shows a summary of the articles included in the study. ...

... Saudi Arabia (46), China (21), and Canada (38) each contributed to publish one relevant study. Most of the article (n = 17) were published in 2022 [32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48]. Table 2 shows a summary of the articles included in the study. ...

... The program has been proven to improve quality of life and subjective cognition. 37 The program is currently disseminated throughout the Unites States and can be delivered virtually. ...

... Yet, recent data show that adherence to the new recommendation is troublingly lowonly 8%, with nearly all (95%) of nonadherence reflecting earlier colonoscopy use than guidelines recommend (35). These low-risk surveillance colonoscopies use a large share of colonoscopy capacity [surveillance for low-risk adenomas is the most common indication for colonoscopy among adults aged older than 70 years (36)], and this share is expected to grow with implementation of the new US Preventive Services Task Force guidelines and new quality metrics (adenoma detection rates), as well as technological advances that incentivize and enable detection of smaller polyps (19,37). A recently launched comparativeeffectiveness study, Colonoscopy vs Stool-based Testing for Older Adults With a History of Colon Polyps (GC is co-investigator), assesses effectiveness of fecal immunochemical testing in place of colonoscopy for patients with a history of low-risk adenomas. ...

... An estimated 2 million patients worldwide receive these antimetabolite drugs annually to treat a variety of solid tumors such as colorectal, pancreatic, breast, and head and neck cancers [1]. About 30% of patients develop severe FP-associated toxicity, including diarrhea, hand-foot syndrome, mucositis, and myelosuppression, which can be fatal for ~ 0.1% of patients [3,4]. ...